Tyrosine kinase domain mutation in chronic myeloid leukemia and its resistance to imatinib. a systematic review | [journal of Peoples University of medical and Health Sciences, Pakistan. • 2023]

Author(s):

1. Muhammad Arif: . Ph.D Scholar of Hematology, Assistant Professor of Hematology, Jinnah Medical College,Peshawar,Pakistan

2. Huma Riaz: Department of Pathology, Hayatabad Medical Complex,Peshawar,Pakistan

3. Muhammad Nisar Khan: Heamotologist, Regional Blood Center,Peshawar,Pakistan

4. Muhammad Ibrahim: Hematology, Institute of Pathology and Diagnostic Medicine, Khyber Medical University,Peshawar,Pakistan

5. Syed Abbas Anwar: Ayub Medical College, Abbottabad, Pakistan

6. Anees Muhammad: Department of Pathology, Govt. Naseerullah Khan Babar Memorial Hospital,Peshawar,Pakistan

Abstract:

The therapy of chronic myeloid leukaemia CML is significantly hampered by the formation of imatinib resistance in patients, notably as a result of tyrosine kinase domain TKD mutations. The goal of this systematic review is to provide a thorough analysis of TKD mutations and their connection to imatinib resistance in CML. To find relevant papers, a comprehensive search approach was used. Then, inclusion criteria were used to select studies for analysis. Data extraction was carried out to collect pertinent information on study characteristics, TKD mutations, imatinib resistance, and clinical outcomes after the risk of bias in the chosen studies was evaluated. The data will be combined numerically and qualitatively, taking into account any heterogeneity and potential biases within the studies that were included. The goals of this review are to ascertain the connection between TKD mutations and the emergence of imatinib resistance in CML and to investigate alternative treatment modalities and their effects on clinical outcomes in CML patients who have developed imatinib resistance. The results of this study will further our knowledge of TKD mutations, point out areas that need more research, and provide guidance for the creation of innovative treatment strategies to overcome imatinib resistance in CM patients. In the end, this study intends to enhance patient outcomes in the age of targeted medications and contribute to the optimisation of CML therapy regimens.

Page(s): 133-141

DOI: 10.46536/jpumhs/2023/13.03.461

Published: Journal: journal of Peoples University of medical and Health Sciences, Pakistan., Volume: 13, Issue: 3, Year: 2023

Keywords:

clinical outcomes , Tyrosine kinase domain TKD mutations , Chronic Myeloid Leukaemia CML , Imatinib resistance

References:

References are not available for this document.

Citations

Citations are not available for this document.

Citations

Downloads

Views